Late-stage biopharmaceutical company Cadrenal Therapeutics Inc (Nasdaq: CVKD) announced on Wednesday that it has been added as a member of the Corporate Council of the Anticoagulation Forum (AC Forum), the largest professional organisation of anticoagulation specialists.

Through participation in the Corporate Council, Cadrenal Therapeutics will collaborate with the AC Forum as it works to identify and address unmet clinical needs, share cutting-edge research, and promote advocacy and educational initiatives for the organisation's 15,000 healthcare professional members, aimed at improving outcomes for patients on anticoagulants.

Quang X Pham, Cadrenal Therapeutics chief executive officer, said: "Our membership in the AC Forum's Corporate Council reflects our shared commitment to transforming anticoagulation care. We look forward to partnering with the AC Forum and contributing to programmes that advance safer, more effective care and inform about ongoing research and anticoagulation best practice guidelines."